EKEnas M. Kamal

Enas M. Kamal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Enas M. Kamal has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Non-invasive Evaluation of Liver Fibrosis Changes in Patients with Chronic ‎Hepatitis C after Directly Acting Antiviral Drugs

    by Taha M Hassanin, Hala Ibraheem, Madeha Makhlouf, Waleed Mahmoud, Nadia El-Ameen, Enas Kamal

    Background and study aims: Liver biopsy is the standard method to assess hepatic fibrosis, but it is unpractical as it is invasive ‎and not agreed by most patients. So, many non-invasive methods for evaluating liver fibrosis ‎have been used including fibrosis-4 (Fib-4) score. We aimed to evaluate hepatic fibrosis changes ‎in patients with chronic hepatitis C after directly acting antiviral therapy.‎ Patients and Methods: ‎‎‎ ‎162 chronic hepatitis C patients were given directly acting anti-viral drugs (DAAs): sofosbuvir ‎‎(400 mg/d) plus daclatasvir (60 mg/d), with or without Ribavirin (600 mg/d) for 12 weeks. Liver ‎fibrosis was assessed before and 48 weeks after end of treatment (EOT) through evaluation of: 1- ‎Serum tissue inhibitor of metalloproteinases-1 (TIMP-1), 2- Liver fibrosis score (Fib-4 score), 3- ‎Liver stiffness measurement (LSM) using Shear Wave Elastography (SWE)‎.‎ Results: sustained virological response was achieved in 95.1% of cases at 48 weeks after EOT. Liver ‎fibrosis was improved at 48 weeks after EOT as evidenced by significant decline in serum level of ‎TIMP-1, significant improvement in Fib-4 score, and significant decline in LSM values using ‎SWE. Multivariate regression analysis showed that higher baseline ALT level and higher ‎baseline liver fibrosis score were predictive of liver stiffness. Conclusion:DAAs therapy showed not only high success rate in HCV eradication (95.1%), ‎but also lead to significant improvement in liver fibrosis‎ ‎‎‎‎‎‎‎‎.


  • Effects of sofosbuvir/ledipasvir therapy on chronic hepatitis C virus genotype 4, infected children of 3‐6 years of age

    by Enas M. Kamal, Mortada El‐Shabrawi, Hisham El‐Khayat, Mostafa Yakoot, Yehia Sameh, Yasser Fouad, Dina Attia

    Background & Aims: Treatment of children aged 3‐6 genotype 4 is still limited by the interferon side effects. We aimed in this study to evaluate the effectiveness and safety of sofosbuvir/ledipasvir in children (3‐6 years) genotype 4 chronic HCV‐infected patients.Methods: In total, 22 consecutive chronic HCV‐infected patients (mean age 4.8 ± 0.9years, 19 males) were included in this prospective study. All patients received sofosbuvir 200 mg/ledipasvir 45 mg in a single oral daily dose. Patients were randomly subdivided into two groups according the duration of treatment into 8 and 12 weeks. All the clinical and laboratory data were collected. All the side effects were recorded from the patients or their parents. Follow‐up were made at Week 4, 8 and 12 and 12 weeks after the end of treatment (SVR12).Results: The overall SVR12 rate was 100%. At Week 4, 9/11 patients in the 12‐week group (81.8%; 95% CI: 52.3%‐94.7%) achieved virologic negativity, vs 10/11 (90.9%; 95% CI: 62.3%‐98.4%) in the 8‐week group. At Week 8, 10/11 (90.8%; 95% CI: 62.3%‐98.4%) in the 12‐week group vs 11/11 (100%; 95% CI: 74.1%‐100%) in the 8‐week group were virologically negative. The reported side effects were cough, abdominal pain, nausea, vomiting and diarrhoea especially early in the treatment. The main complaint was difficulty in swallowing the tablets in the youngest patient at the beginning of the course of treatment. All patients were compliant to treatment.Conclusion: Sofosbuvir/ledipasvir combination is safe and tolerable in the chronic infected HCV genotype 4 infected children (3‐6 years). The 8‐week treatment duration is similarly effective as the 12‐week duration.


  • A pilot single arm observational study of sofosbuvir/ledipasvir (200 + 45 mg) in 6‐ to 12‐ year old children

    by M. H. F. El‐Shabrawi, N. M. Kamal, H. R. El‐Khayat, E. M. Kamal, M. M. A. H. AbdElgawad, M. Yakoot

    Summary: Background: No available data on the use of sofosbuvir/ledipasvir combination in treatment of hepatitis C virus (HCV) infection in children 6‐ to 12‐ year old.Aim: To assess the safety and efficacy of sofosbuvir plus ledipasvir in children 6‐ to 12‐ year old with chronic HCV genotype 4 infection.Methods: This is a pilot prospective single arm observational open‐label multicentre study. A total of 20 consecutive eligible chronic HCV infected children, aged from 6‐ to 12‐ years were included in this study and treated with a fixed sofosbuvir/ledipasvir combination in half the adult dose (200/45 mg) once daily for 12 weeks. Laboratory tests including virological markers were measured at baseline, 2, 4, 8 and 12 weeks (end of treatment [EOT]), and 12 weeks after end of treatment for sustained virological response 12 (SVR12).Results: The intention‐to‐treat (ITT) SVR12 rate was 19/20 (95%; 95% CI: 76.4%‐99.1%). SVR12 was not assessed in one patient who was lost to follow‐up after showing viral negativity at the EOT12. All the remaining 19 patients (100%, 95% CI: 83.18%‐100%) who completed the full protocol and follow‐up visits achieved SVR12 with normal liver, haematological, and renal function tests and no side effects or fatalities.Conclusions: This pilot study demonstrated that the fixed dose sofosbuvir/ledipasvir combination could be safe and effective treatment in children 6‐ to 12‐ years with chronic hepatitis C genotype 4 infection. Our pilot results might encourage larger and multicentre studies in this age group.


  • The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real‐world experience

    by H. R. El‐Khayat, E. M. Kamal, M. H. El‐Sayed, M. El‐Shabrawi, H. Ayoub, A. RizK, M. Maher, R. Y. El Sheemy, Y. M. Fouad, D. Attia

    Summary: Background: The combination of ledipasvir plus sofosbuvir was recently approved for treatment of adolescent (12‐17 years) HCV genotype 1, 4, 5 & 6 patients. However, few clinical trials have been performed in genotype 1 patients.Aim: To investigate the effectiveness and safety of ledipasvir plus sofosbuvir in chronic HCV adolescent patients with genotype 4 in the real world.Methods: This prospective multicentre (six centres) open‐label study included 144 adolescent chronic HCV patients with genotype 4 (mean age 14 ± 2, 69% males). All patients received a combination tablet containing 400 mg sofosbuvir and 90 mg ledipasvir once daily for 12 weeks. Laboratory and virological markers were evaluated at baseline, week 4, week 8 and week 12 (EOT), and 12 weeks after end of treatment (SVR12).Results: SVR12 was observed in 142/144 patients (99%). The relapsers occurred in previous naïve patients (n = 2/128, 2%), while the experienced patients showed 100% SVR12. SVR12 was 98% in F0/F1 patients in comparison to 100% in F2 patients (P = 0.552). No serious side effects were observed, nor was treatment discontinuation or death. Headache was the most common side effect in all patients (20%). In experienced patients, pruritus (31%, P = 0.007), diarrhoea (44%, P < 0.001) and skin rash (19%, P = 0.002) were higher than in naïve patients.Conclusions: A ledipasvir plus sofosbuvir regimen is well tolerated and effective, and can be used safely in treating adolescent patients with chronic hepatitis C genotype 4.


  • Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C‐related cirrhosis, genotype 4

    by H. El‐Khayat, Y. Fouad, H. I. Mohamed, H. El‐Amin, E. M. Kamal, M. Maher, A. Risk

    Summary: Background: The Daclatasvir and Sofosbuvir combination therapy (SOF/DCV) has shown efficacy in patients with chronic hepatitis C in clinical trials.Aim: To investigate the efficacy and safety of SOF/DCV for treatment of patients with hepatitis C‐related liver cirrhosis genotype 4.Methods: Multicentre study involving 551 patients with liver cirrhosis genotype 4; 432 naïve patients and 119 treatment‐experienced patients. All patients received SOF (400 mg) and DCV (60 mg) daily in addition to weight‐based ribavirin (RBV) for 12 weeks and when RBV is contraindicated the treatment duration was extended to 24 weeks.Results: Sustained virological response at 12 weeks after end of treatment (SVR12) rate was 92% in naïve cirrhotic patients and 87% in previous treated patients (by ITT analysis). Virological failure was infrequent, occurring in 42 patients (8%) overall. Thirty‐two (6%) were non responders; and 10 (2%) cases were relapsers, 31 patients (7%) were CTP‐A and 11 (13.3%) patients were CTP‐B (by ITT analysis). The most common adverse events were anaemia, fatigue, headache, pruritus. Serious side effects were recorded mainly in CTP‐B cirrhotic patients including HCC and hepatic encephalopathy.Conclusions: The SOF/DCV combination therapy has proven efficacy and safety in treating patients with hepatitis C‐related liver cirrhosis genotype 4 in a large cohort of patients in the real world.


  • Expression of Proteinase-activated Receptor-2 in the Esophageal Mucosa of Gastroesophageal Reflux Disease Patients

    by Dalia M. Abd El-Rehim, Hanaa K. Fath El-Bab, Enas M. Kamal

    Data are limited regarding the role of proteinase-activated receptor-2 (PAR-2) in the esophageal mucosa in gastroesophageal reflux disease (GERD) patients. Our aim was to study PAR-2 expression and its relationship with different GERD-related clinical and pathologic parameters. Histomorphologic alterations in eosophageal mucosa in nonerosive reflux disease (NERD) and erosive reflux disease (ERD) were also, evaluated. Endoscopic biopsies of the esophageal mucosa were obtained from 94 GERD patients and 20 participants for histopathologic analysis and PAR-2 immunohistochemical staining. The present study demonstrated significantly higher PAR-2 expression in GERD patients compared with control, whereas no significant differences were seen between NERD and ERD groups. PAR-2 expression significantly correlated with histologic score (r=0.572, Pr=0.541, PPPr=0.299, P=0.025) and endoscopic severity (r=0.359, P=0.027) in NERD and ERD patients, respectively. Taken together, this study provides evidence for the major role of PAR-2 in the pathogenesis of GERD and GERD-associated mucosal alterations.